Oncology and Hematology News and Journal Articles
Cancer Network presents exclusive coverage from the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. We’ll bring you reports and interviews of the latest research, trials, scientific advances, and controversies that are changing the way cancer is managed and treated.
Ahead of the ESMO World Congress on Gastrointestinal Cancer, we are discussing the use of maintenance therapy in metastatic colorectal cancer with Axel Grothey, MD.
The FDA has granted a priority review for MM-398 as a second-line treatment for metastatic pancreatic cancer after the drug demonstrated improved survival.
Frequent consumers of citrus fruits were found to have an elevated risk of malignant melanoma.
The combination of pemetrexed/cisplatin was superior to gemcitabine/cisplatin in non-squamous NSCLC patients negative for the thymidylate synthase enzyme.
Researchers have discovered a protein encoded by the GPC1 gene present on cancer exomes that may be used as a diagnostic tool to detect early pancreatic cancer.
In this video, Dr. Paz-Ares discusses a phase III study that showed that nivolumab improved survival and response rates in previously treated patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
In this video, Steven I. Sherman, MD, discusses the final overall survival analysis of the EXAM study, a randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients.
In this video, Dr. El-Khoueiry discusses results from a phase I/II study that suggest the PD-1 inhibitor nivolumab is safe and effective in advanced hepatocellular carcinoma.
In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.
This thyroid cancer slide show features pathology images of follicular carcinoma and Hurthle cell carcinoma at various magnifications.
This slide show features various magnifications of tumors of the middle ear, including a endolymphatic sac tumor, a meningioma, and a paraganglioma.